abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Disclosure

15 Apr 2022

Author:
AbbVie

AbbVie statement

15 April 2022

...Hope all is well and apologies for the delay in getting back to you. For your questions regarding Ukraine, we would direct you to our company webpage that speaks to this issue – please see here: https://www.abbvie.com/ukraine.html

We will be sure to keep you updated and please let me know if you need anything further.

Thank you for reaching out and apologies again for the delay...

20 April 2022

As a follow up, I wanted to pass along the news we made yesterday that AbbVie will donate profits from Russia to humanitarian relief efforts in Ukraine. Please see below for our statement from yesterday:

AbbVie Will Donate Profits from Russia to Humanitarian Relief Efforts

We are committed to doing everything possible to support the people of Ukraine and those impacted across the region. Our primary focus continues to be the safety of our colleagues and ensuring patients have access to the medicines they need.

As a company dedicated to the health of patients, we will continue to supply our essential life-saving medicines in Russia. Today, we are announcing that all profits from sales of AbbVie’s essential medicines in Russia will be donated to support direct humanitarian relief efforts in Ukraine.

In addition, we previously announced the suspension of all sales and distribution of our aesthetics products in Russia. We have also halted new clinical studies and ceased enrollment of ongoing studies in Ukraine and Russia.

Our work with nonprofit partners and employees to support humanitarian relief efforts in Ukraine will continue as we hope for a peaceful resolution.

For more information on our full response, visit https://www.abbvie.com/ukraine.html.

Timeline